Figures computed from official regulatory filings — .
Analysttarget 57 USD (+237%) · consensus 5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 47.91% · institutions 12.25% · short 21.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Greenwich LifeSciences, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
122 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Patel Snehaltrack record | Buy | $9.2K | conv 29 |
| Patel Snehaltrack record | Buy | $20.4K | conv 29 | SEC |
| Patel Snehaltrack record | Buy | $20.4K | conv 29 | SEC |
| Patel Snehaltrack record | Buy | $14.2K | conv 29 | SEC |
| Patel Snehaltrack record | Buy | $32.9K | conv 35 | SEC |
| Patel Snehaltrack record | Buy | $53.7K | conv 21 | SEC |
| Patel Snehaltrack record | Buy | $79.9K | conv 31 | SEC |
| Patel Snehaltrack record | Buy | $91.8K | conv 39Unusual size | SEC |
| Patel Snehaltrack record | Buy | $63K | conv 17 | SEC |
| Patel Snehaltrack record | Buy | $51.7K | conv 18 | SEC |
| Patel Snehaltrack record | Buy | $38.5K | conv 28 | SEC |
| Patel Snehaltrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Patel Snehaltrack record | Buy | $89.4K | conv 27 | SEC |
| Patel Snehaltrack record | Buy | $21.3K | conv 32 | SEC |
| Patel Snehaltrack record | Buy | $35.6K | conv 16 | SEC |
| Patel Snehaltrack record | Buy | $48.5K | conv 17 | SEC |
| Patel Snehaltrack record | Buy | $32.8K | conv 16 | SEC |
| Patel Snehaltrack record | Buy | $48K | conv 20 | SEC |
| Patel Snehaltrack record | Buy | $31.3K | conv 26 | SEC |
| Patel Snehaltrack record | Buy | $24.8K | conv 17 | SEC |
| Patel Snehaltrack record | Buy | $14.6K | conv 26 | SEC |
| Patel Snehaltrack record | Buy | $44K | conv 26 | SEC |
| Patel Snehaltrack record | Buy | $23.9K | conv 27 | SEC |
| Patel Snehaltrack record | Buy | $27.3K | conv 28 | SEC |
| Patel Snehaltrack record | Buy | $35.6K | conv 28 | SEC |